Dimeric Bacteriophage Lysins for Streptococcus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial approaches, particularly against Streptococcus bacteria, face challenges such as drug resistance, limited penetration through mucus linings, allergic reactions, and the need for longer treatment times due to the inefficacy of existing antibiotics and the complexity of using bacteriophages for direct treatment.
Innovation Solution
Development of dimeric phage lysins, specifically dimeric pneumococcal phage lysins like Cpl-1, which are chemically cross-linked to enhance stability and activity, allowing for prolonged bacterial killing capability and reduced plasma clearance, thereby improving treatment efficacy for Streptococcus infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If monomeric lysins are used, then the structure is simple and easy to manufacture, but the plasma clearance is rapid and stability is reduced
Solution Approach 1:
The patent combines two monomeric lysin units to form a dimeric lysin structure. This merging of two identical or similar lysin monomers creates a larger molecular entity that exhibits reduced plasma clearance and enhanced stability compared to the monomeric form, while maintaining the bacterial cell wall targeting capability
Solution Approach 2:
The dimeric lysin can be constructed using composite strategies such as fusing two lysin coding sequences with a linker peptide, or chemically cross-linking two purified lysin monomers. This creates a composite protein structure that leverages the properties of individual monomers while achieving superior pharmacokinetic properties
2Stability of the object's composition
If dimeric lysins are used, then plasma stability is improved and clearance is reduced, but the manufacturing complexity increases
Solution Approach 1:
The dimeric lysin is segmented into two distinct lysin monomer units that can be independently produced and then assembled. This segmentation allows for modular manufacturing where each monomer can be optimized separately, and the dimerization can be achieved through controlled chemical cross-linking or fusion protein expression
Solution Approach 2:
A linker peptide serves as an intermediary element that connects two lysin monomers to form a stable dimeric structure. This intermediary component facilitates the association of monomers while maintaining the functional integrity of each lysin unit, and can be designed to provide appropriate spacing and orientation for optimal activity
3Reliability
If bacteriophages are used for direct treatment, then bacterial targeting is achieved, but the treatment protocol becomes complex and requires synchronized growth cycles
Solution Approach 1:
The patent extracts the active lysin enzyme from the bacteriophage system and uses it as a standalone therapeutic agent. This extraction eliminates the need for the complex phage replication cycle and synchronized growth requirements, while retaining the lysin's specific bacterial cell wall targeting capability. The lysin can be produced recombinantly and administered directly
Solution Approach 2:
The lysin enzyme inherently possesses self-service capabilities through its natural affinity for bacterial cell wall components. The lysin automatically targets and binds to specific peptidoglycan structures in Streptococcus bacteria without requiring phage-mediated delivery or complex activation sequences, enabling straightforward therapeutic application
4Ease of operation
If existing antibiotics are used, then treatment is simple to administer, but drug resistance develops and treatment duration increases
Solution Approach 1:
The patent converts the previously harmful or ineffective situation of antibiotic resistance into a beneficial outcome by using a completely different mechanism of action. Instead of inhibiting bacterial growth like traditional antibiotics, the dimeric lysin directly lyzes the bacterial cell wall, a mechanism to which bacteria have not developed resistance. This transforms the resistance problem into an opportunity for effective treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dimeric lysins demonstrate increased bacterial killing activity and prolonged stability, potentially reducing treatment duration and allergic reactions, while maintaining effective targeting of Streptococcus bacteria, including Streptococcus pneumoniae.
Implementation Method 1
chemically cross-linked to enhance stability and activity
Implementation Method 2
lysins that break bonds in the bacterial wall... rapidly hydrolyzes covalent bonds essential for peptidoglycan integrity
Data Source
Figure 1
Figure 2(A)~2(C)
Figure 3
AI summary
The present invention provides an isolated dimeric phage lysin comprising two phage lysin monomers specific for bacteria covalently linked to each other and capable of killing at least one or more Streptococcus bacteria.